Vistagen Therapeutics (VTGN) Debt Ratio (2011 - 2026)

Vistagen Therapeutics (VTGN) posted Debt Ratio of 0.0 for Q1 2026, down 96.05% sequentially from 0.05 in Q2 2023.

Vistagen Therapeutics (VTGN) Debt Ratio (2011 - 2026) Analysis & Trends

Vistagen Therapeutics has reported Debt Ratio for 11 years, with the latest figure at 0.0 in Q1 2026.

Quarterly Debt Ratio changed N/A year-over-year to 0.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0 (changed N/A YoY) and the FY2026 annual result came in at 0.0, changed N/A from the prior year.
Debt Ratio declined to 0.0 in Q1 2026 per VTGN's latest filing, from 0.05 in the prior quarter.
Over five years, Debt Ratio peaked at 0.05 in Q2 2023 and troughed at 0.0 in Q1 2026.
A 3-year average of 0.02 and a median of 0.02 in 2022 frame the typical range for Debt Ratio.
The widest YoY moves for Debt Ratio: up 195.2% in 2023, down 195.2% in 2023.
Over 3 years, Debt Ratio stood at 0.01 in 2022, then soared by 269.8% to 0.05 in 2023, then slumped by 96.05% to 0.0 in 2026.
According to Business Quant data, Debt Ratio over the past three periods registered 0.0, 0.05, and 0.0 for Q1 2026, Q2 2023, and Q1 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	0.05
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	0.26
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.47
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	0.03
10	Vistagen Therapeutics	10.35 Mn	10.35 Mn	-	-

Download Data